A first proof of concept for Nox2 as a principal source of ROS in stroke was provided in 1997 when Walder et al. showed strong protection for the damage of transient MCAO in Nox2-deficient mice [25], raising strong interest in targeting Nox2 as a potential therapy for stroke. This evidence concerns the gene CYBB and Stroke.